GEMSTONE Oncology logo
MenuClose

Therapeutic Options for Recurrent Platinum-Sensitive Ovarian Cancer

  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide
  • slide

Download Slide Module

Treatment options for recurrent platinum-sensitive ovarian cancer are evolving.

Most advanced ovarian cancers will recur during or after first-line treatment. Median progression-free survival decreases upon each subsequent recurrence. Patients with ovarian cancer whose disease recurs at least 6 months after treatment completion are considered to be platinum- or chemotherapy-sensitive.

Management options for these patients may include platinum-based combination chemotherapy, secondary cytoreductive surgery, and maintenance therapy. PARP inhibitors and anti-angiogenic agents are also being evaluated as a combination approach.

Explore the module further to learn more about therapies for recurrent platinum-sensitive ovarian cancer—or download the module for later review offline.

Many new treatment options have become available to patients with platinum-sensitive ovarian cancer in recent years, including targeted agents in the maintenance setting. Understanding these options is critical when determining the next course of therapy.

MATTHEW A. POWELL, MD
Washington University
GEMSTONE Committee Member: Matthew A. Powell, MD
GEMSTONE Oncology infographic ‐ Treatment Options for Recurrent Platinum ‐ Sensitive Ovarian Cancer

Download Infographic